{"id":"cdc-501","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a cereblon-binding agent, CDC-501 recruits target proteins to the cereblon E3 ubiquitin ligase complex, leading to their proteasomal degradation. This mechanism is similar to other immunomodulatory drugs (IMiDs) developed by Celgene and is designed to modulate immune function and inhibit proliferation of disease-causing cells.","oneSentence":"CDC-501 is a cereblon E3 ligase modulator that degrades specific proteins involved in immune regulation and cell proliferation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:57:33.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (phase 2 development)"}]},"trialDetails":[{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT01711554","phase":"PHASE1","title":"Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-02-04","conditions":"Recurrent Neuroblastoma, Refractory Neuroblastoma","enrollment":27},{"nctId":"NCT02160015","phase":"PHASE1","title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-20","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT06015880","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-20","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":120},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT01829568","phase":"PHASE1","title":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-06-26","conditions":"Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma","enrollment":33},{"nctId":"NCT01522976","phase":"PHASE2","title":"Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-03-01","conditions":"Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2","enrollment":282},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT00843882","phase":"PHASE3","title":"Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-01-29","conditions":"Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome","enrollment":247},{"nctId":"NCT05025800","phase":"PHASE1, PHASE2","title":"ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-13","conditions":"Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":47},{"nctId":"NCT03359460","phase":"PHASE1","title":"Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2017-12-01","conditions":"Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome","enrollment":4},{"nctId":"NCT03477539","phase":"PHASE2","title":"Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-04-09","conditions":"Plasma Cell Myeloma","enrollment":49},{"nctId":"NCT02446457","phase":"PHASE2","title":"Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma","enrollment":53},{"nctId":"NCT00602641","phase":"PHASE3","title":"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-29","conditions":"Multiple Myeloma","enrollment":306},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":"Smoldering Plasma Cell Myeloma","enrollment":288},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT05861050","phase":"PHASE1, PHASE2","title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-10","conditions":"Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma","enrollment":50},{"nctId":"NCT06723457","phase":"PHASE2","title":"Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2025-07-25","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":34},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":"Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":35},{"nctId":"NCT04876248","phase":"PHASE2","title":"Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-08-19","conditions":"Plasma Cell Myeloma","enrollment":4},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":"ISS Stage III Plasma Cell Myeloma, Multiple Myeloma","enrollment":17},{"nctId":"NCT02389517","phase":"PHASE2","title":"Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2015-03-02","conditions":"Plasma Cell Myeloma, Residual Disease","enrollment":42},{"nctId":"NCT02619682","phase":"PHASE2","title":"Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-12-30","conditions":"Plasma Cell Myeloma, Transplant-Related Carcinoma","enrollment":30},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT03631043","phase":"EARLY_PHASE1","title":"Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-12-21","conditions":"Smoldering Plasma Cell Myeloma","enrollment":30},{"nctId":"NCT06112847","phase":"PHASE2","title":"Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2024-01-24","conditions":"Follicular Lymphoma","enrollment":29},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT02568553","phase":"PHASE1","title":"Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-11-15","conditions":"Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":35},{"nctId":"NCT01169337","phase":"PHASE3","title":"Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-01-24","conditions":"Light Chain Deposition Disease, Smoldering Multiple Myeloma","enrollment":226},{"nctId":"NCT00114101","phase":"PHASE3","title":"Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-12-15","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":460},{"nctId":"NCT01351896","phase":"PHASE2","title":"Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-02","conditions":"Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":49},{"nctId":"NCT05821088","phase":"PHASE2","title":"Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"David Bond, MD","startDate":"2023-06-29","conditions":"Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":37},{"nctId":"NCT01955499","phase":"PHASE1","title":"Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-09-24","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma","enrollment":39},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":62},{"nctId":"NCT05890352","phase":"PHASE2","title":"Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-09-26","conditions":"Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","enrollment":227},{"nctId":"NCT02420860","phase":"PHASE2","title":"Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-04-14","conditions":"Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma","enrollment":113},{"nctId":"NCT03015896","phase":"PHASE1, PHASE2","title":"Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bond, MD","startDate":"2017-02-14","conditions":"Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":36},{"nctId":"NCT03011814","phase":"PHASE1, PHASE2","title":"Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-03-08","conditions":"Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides","enrollment":38},{"nctId":"NCT04447716","phase":"PHASE1","title":"An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2020-10-16","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma","enrollment":4},{"nctId":"NCT02992522","phase":"PHASE1","title":"Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Christian","startDate":"2017-02-21","conditions":"B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma","enrollment":22},{"nctId":"NCT01863550","phase":"PHASE3","title":"Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-12-06","conditions":"Plasma Cell Myeloma","enrollment":1087},{"nctId":"NCT05288062","phase":"PHASE2","title":"Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2022-06-15","conditions":"Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":17},{"nctId":"NCT03015792","phase":"PHASE1","title":"Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2017-03-10","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":18},{"nctId":"NCT03409432","phase":"PHASE2","title":"Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma","status":"COMPLETED","sponsor":"John Reneau","startDate":"2018-03-16","conditions":"Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","enrollment":26},{"nctId":"NCT01995669","phase":"PHASE1, PHASE2","title":"Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-05-27","conditions":"Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":66},{"nctId":"NCT01668719","phase":"PHASE1, PHASE2","title":"S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2012-11","conditions":"DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma","enrollment":142},{"nctId":"NCT02871219","phase":"PHASE2","title":"Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-06","conditions":"Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma","enrollment":96},{"nctId":"NCT03012880","phase":"PHASE2","title":"Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-04-20","conditions":"Plasma Cell Myeloma","enrollment":80},{"nctId":"NCT05561387","phase":"PHASE3","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-10-12","conditions":"Plasma Cell Myeloma","enrollment":510},{"nctId":"NCT03941860","phase":"PHASE3","title":"Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-16","conditions":"Multiple Myeloma","enrollment":1},{"nctId":"NCT04892264","phase":"PHASE1","title":"Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2021-06-03","conditions":"Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":5},{"nctId":"NCT02334865","phase":"PHASE1","title":"SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2017-04-13","conditions":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma","enrollment":18},{"nctId":"NCT01729091","phase":"PHASE2","title":"Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-06-10","conditions":"Plasma Cell Leukemia, Plasma Cell Myeloma","enrollment":72},{"nctId":"NCT04578600","phase":"PHASE1","title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","status":"COMPLETED","sponsor":"Joseph Tuscano","startDate":"2020-10-23","conditions":"Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia","enrollment":8},{"nctId":"NCT04404088","phase":"PHASE2","title":"Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-16","conditions":"Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":60},{"nctId":"NCT02921893","phase":"EARLY_PHASE1","title":"Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-10-31","conditions":"Plasmacytoma, POEMS Syndrome","enrollment":21},{"nctId":"NCT01718743","phase":"PHASE2","title":"Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-12-03","conditions":"Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma","enrollment":64},{"nctId":"NCT01553149","phase":"PHASE2","title":"Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-05","conditions":"Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma","enrollment":75},{"nctId":"NCT01919619","phase":"PHASE2","title":"Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-11-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia","enrollment":41},{"nctId":"NCT05910801","phase":"PHASE2","title":"Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2024-01-04","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":100},{"nctId":"NCT02532257","phase":"PHASE2","title":"Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-04-11","conditions":"Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma","enrollment":48},{"nctId":"NCT02628405","phase":"PHASE1, PHASE2","title":"R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2016-05-20","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT04352205","phase":"PHASE2","title":"Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-05-07","conditions":"Plasma Cell Myeloma, Renal Failure","enrollment":17},{"nctId":"NCT02636322","phase":"PHASE2","title":"Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-03-29","conditions":"Diffuse Large B-Cell Lymphoma Unclassifiable","enrollment":60},{"nctId":"NCT02697344","phase":"PHASE1","title":"Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-04-14","conditions":"Recurrent Plasma Cell Myeloma","enrollment":10},{"nctId":"NCT02561273","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-09-28","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma","enrollment":54},{"nctId":"NCT01035463","phase":"PHASE1, PHASE2","title":"Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-11-12","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":74},{"nctId":"NCT01772420","phase":"PHASE2","title":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-10","conditions":"Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia","enrollment":52},{"nctId":"NCT01145495","phase":"PHASE2","title":"Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06-15","conditions":"Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma","enrollment":66},{"nctId":"NCT00602459","phase":"PHASE2","title":"Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-01-15","conditions":"Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia","enrollment":418},{"nctId":"NCT03019640","phase":"PHASE2","title":"Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-10","conditions":"Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma","enrollment":22},{"nctId":"NCT03252600","phase":"PHASE2","title":"Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis","status":"UNKNOWN","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2017-08-25","conditions":"Recurrent Primary Amyloidosis","enrollment":53},{"nctId":"NCT02126553","phase":"PHASE2","title":"Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-11-13","conditions":"Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia","enrollment":29},{"nctId":"NCT04635683","phase":"PHASE1","title":"Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"Yazeed Sawalha","startDate":"2022-09-30","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Follicular Lymphoma","enrollment":""},{"nctId":"NCT02225275","phase":"PHASE2","title":"Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-03-31","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":9},{"nctId":"NCT01886859","phase":"PHASE1","title":"Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-04-26","conditions":"Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma","enrollment":27},{"nctId":"NCT02086552","phase":"PHASE2","title":"Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-01-17","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":28},{"nctId":"NCT00695786","phase":"PHASE2","title":"Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-10","conditions":"Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma","enrollment":156},{"nctId":"NCT01208051","phase":"PHASE1, PHASE2","title":"Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-09","conditions":"Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma","enrollment":127},{"nctId":"NCT02309515","phase":"PHASE2","title":"Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-06-11","conditions":"Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT00966693","phase":"PHASE1, PHASE2","title":"Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-08-25","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":77},{"nctId":"NCT03506802","phase":"PHASE1","title":"TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-07-10","conditions":"HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT01003769","phase":"PHASE1, PHASE2","title":"Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-07-09","conditions":"Recurrent Chronic Lymphocytic Leukemia","enrollment":5},{"nctId":"NCT02038153","phase":"PHASE1, PHASE2","title":"Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-12","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission","enrollment":3},{"nctId":"NCT02492750","phase":"PHASE1","title":"Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-04","conditions":"Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma","enrollment":14},{"nctId":"NCT01254617","phase":"PHASE1","title":"Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-10","conditions":"Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT01619761","phase":"PHASE1","title":"NK Cells in Cord Blood Transplantation","status":"UNKNOWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-05-03","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission","enrollment":13},{"nctId":"NCT00046735","phase":"PHASE1","title":"Phase 1 Study OF CDC-501 in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Celgene","startDate":"2002-06-01","conditions":"Neoplasms","enrollment":24},{"nctId":"NCT00445692","phase":"PHASE2","title":"Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-01-10","conditions":"DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma","enrollment":32},{"nctId":"NCT00044018","phase":"PHASE2","title":"CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2002-04-01","conditions":"Multiple Myeloma","enrollment":102},{"nctId":"NCT01076543","phase":"PHASE1, PHASE2","title":"Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-04-15","conditions":"AIDS-Related Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Follicular Lymphoma","enrollment":110},{"nctId":"NCT03232307","phase":"PHASE2","title":"Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-01","conditions":"CCND1 Positive, CD20-Positive Neoplastic Cells Present, Mantle Cell Lymphoma","enrollment":""},{"nctId":"NCT02880228","phase":"PHASE2","title":"Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-09-16","conditions":"Plasma Cell Myeloma","enrollment":11},{"nctId":"NCT03333746","phase":"PHASE2","title":"Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Yvonne Efebera","startDate":"2018-03-21","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":1},{"nctId":"NCT01002755","phase":"PHASE2","title":"Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-01-19","conditions":"Chronic Lymphocytic Leukemia, Fatigue, Fever","enrollment":36},{"nctId":"NCT03373305","phase":"PHASE1","title":"Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2019-03","conditions":"CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides, Recurrent Mycosis Fungoides","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CDC-501","genericName":"CDC-501","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDC-501 is a cereblon E3 ligase modulator that degrades specific proteins involved in immune regulation and cell proliferation. Used for Multiple myeloma (phase 2 development).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}